Medigen Vaccine Biologics Corporation (6547.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$49.40 (-3.14%) as of
Key statistics
- Market cap
- 16.24B
- Forward P/E
- 33.84
- EPS (TTM)
- -0.49
- Dividend yield
- 0.00%
- 52-week range
- 33.50 – 72.20
- Beta
- -0.02
- Revenue (TTM)
- 573.85M
- Profit margin
- -29.06%
- Analyst target
- NT$102.00
- Volume
- 2.36M
About Medigen Vaccine Biologics Corporation
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. The company has a collaboration with Charles River Laboratories for the development of next-generation multivalent enterovirus vaccines, enhance global regulatory readiness, and support IND-enabling non-clinical studies. The company was incorporated in 2012 and is headquartered in Zhubei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Zhubei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.